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cocci, 04102 Group B, 04103 Group C, 04105 Group G)
IE cases under the category of “streptococcal.” This
has major implications as we evaluate the risk, if any,
of dental procedures and the subsequent development
of IE caused by VGS. In this regard, our ﬁndings (2,3)
and those of Bor et al. (4), which were both derived
from the same database (NIS), did not demonstrate an
increase in IE incidence caused by VGS.
Second, the work by Pant et al. was presented at the
American College of Cardiology 2014 meeting in a pre-
liminary format (5) and they identiﬁed an increase in IE
incidence from2000 to 2011 causedby staphylococci, but
reported that there was no increase in IE caused by
“VGE” (which we assume was in reference to VGS).
Interestingly, therewasnodesignation for “enterococci”
in that abstract for the 2014 meeting, or in the current
publication (1).
The enterococcal designation is an important one
because these organisms are a predominant cause of
IE and its prevalence seems to be increasing. For
example, an extensive systematic review by Slipczuk
et al. (5) of IE over the past 5 decades (up through
2011) demonstrated the prevalence of staphylococcal
and enterococcal IE had both increased; in contrast,
VGS IE had declined.
The only conclusions that we can derive from the
current publication (1) is that there was a key error in
the selection of ICD-9-CM codes to deﬁne the micro-
biology of IE and that has likely resulted in a ﬂawed
conclusion that “there has been a signiﬁcant rise in
the incidence of streptococcus IE following the 2007
guideline revision.” Therefore, we request that Pant
et al. perform a focused analysis of IE caused by VGS
to clarify the issue.
These database reviews are critical as guidelines
committees struggle to answer one of the most
important questions in IE prevention: is antibiotic
prophylaxis for certain dental procedures efﬁcacious?
This struggle, in large part, is caused by the lack of
a randomized controlled clinical trial, as highlighted
in an accompanying editorial and has been a plea
echoed for decades.
Going forward and until clinical trial data are
available, a second plea seems in order. In studies
of cardiovascular infections, a cadre of experts
from different ﬁelds should be included, as done in
individual patient management of IE.*Daniel C. DeSimone, MD
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Incidence, Microbiology, and Valve
Replacement in the United States
From 2000 to 2011
The Devil Is in the DetailsWe thank Dr. DeSimone and colleagues for their in-
terest in our paper. In our study, we focused on
infective endocarditis (IE) microbiology to Staphy-
lococcus, Streptococcus, gram-negative, and fungal
organisms. Our study differs from previous papers
from the Nationwide Inpatient Sample database (1,2)
in 2 aspects. First, we did include infections from all
streptococcal groups (A, B, C, D [enterococcus], G,
and unspeciﬁed) and did not report viridans group
Streptococcus (VGS) separately. Second, previous
studies on IE trends in the United States had a very
limited follow-up of only 2 years after the guideline
publication. Longer follow-up studies are necessary
to assess the impact of any “practice changing”
guideline because it takes years to note the impact
of such change. Similar observations were made in
the United Kingdom where a steady incidence of IE
was noted for the ﬁrst 2 years after publication of
new guidelines, whereas a 5-year follow-up detected
a signiﬁcant rise (3,4). Our study emphasizes the
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1203need for ongoing monitoring of the impact of new
guidelines.
Regarding the preliminary data presented at the
American College of Cardiology 2014 meeting, our data
on VGS were not entirely captured (only ICD9-CM codes
421.0 and 041.00 were used). Furthermore, the VGS IE
diagnosis established by DeSimone et al. (2) raises
serious concern because the VGS does not carry a
unique ICD-9 CM code (unlike staphylococcus, entero-
coccus, and so forth). This etiology was assumed by
including ICD-9 CM code 041.09 or ICD-9 CM code
041.00 (“Streptococcus infection in conditions classi-
ﬁed elsewhere and of unspeciﬁed site, other Strepto-
coccus”) among patients carrying the diagnosis of IE (2).
The accuracy of VGS diagnosis and drawing major
conclusions based on nonspeciﬁc coding can be erro-
neous. Feedback from many experts attending the
American College of Cardiology 2014 meeting helped
us overcome this limitation in our study, resulting
in elimination of VGS group. Hence, our conclusion
“there has been a signiﬁcant rise in the incidence of
streptococcus IE following 2007 guideline” is statisti-
cally sound and the study design valid. Whether the
temporal association noted in our study reﬂects a
causal relationship cannot be deduced from our
study design. We acknowledged this in the limitation
section.
We appreciate the suggestion of DeSimone and
colleagues to look at VGS as a speciﬁc subgroup.
However, as pointed out by Dayer and Thornhill (5),
this has to be done in a randomized controlled design
to eliminate the inherent limitations of a retrospec-
tive database.Sadip Pant, MD
Abhishek Deshmukh, MD
*Jawahar L. Mehta, MD, PhD
*University of Arkansas for Medical Sciences
Division of Cardiovascular Medicine
4301 West Markham Street, Mail Slot 532
Little Rock, Arkansas 72205-7199
E-mail: mehtajl@uams.edu
http://dx.doi.org/10.1016/j.jacc.2015.06.1330
Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
RE F E RENCE S
1. Bor DH, Woolhandler S, Nardin R, et al. Infective endocarditis in the U.S.,
1998–2009: a nationwide study. PLoS One 2013;8:e60033.
2. DeSimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective
endocarditis caused by viridans group streptococci before and after publica-
tion of the 2007 American Heart Association’s endocarditis prevention
guidelines. Circulation 2012;126:60–4.
3. Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline
recommending cessation of antibiotic prophylaxis for prevention of infective
endocarditis: before and after study. BMJ 2011;342:d2392.4. Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocarditis
in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet
2015;385:1219–28.
5. Dayer M, Thornhill M. Antibiotic prophylaxis guidelines and infective
endocarditis: cause for concern? J Am Coll Cardiol 2015;65:2077–8.Impact of Clinical
Presentation on Dual
Antiplatelet Therapy
Duration
Let’s Re-Evaluate Our PrioritiesWe read with interest the paper by Yeh et al. (1)
published in the Journal, reporting on a subgroup
analysis from the DAPT (Dual Antiplatelet Therapy)
trial in which the effect of an extended treatment
with DAPT beyond 1 year was investigated in patients
presenting with or without myocardial infarction
at the time of stent implantation. The authors
concluded that the beneﬁt of an extended treatment
persisted irrespective of the clinical presentation.
We believe the results of this analysis only poorly
support this conclusion for the following motivations.
Reducing mortality is the ultimate goal of cardiovas-
cular medicine. However, the use of combined end-
points, encompassing fatal and nonfatal events, such
as myocardial infarction or cerebrovascular accident,
is necessary to increase study power and limit the
number of patients needed in clinical trials. Death
traditionally comprises a small fraction of such com-
posite outcomes after percutaneous coronary inter-
vention. Therefore, the underlying foundation for
combining fatal and nonfatal outcomes as a reliable
measure of a given treatment effect requires that
nonfatal endpoints are independently associated
with fatal events and that the strength of this asso-
ciation is somewhat comparable across nonfatal
endpoints. The rationale for extending DAPT beyond
the recommended period is to prevent myocardial
infarction, both stent- and nonstent-related, and by
that improving survival.
In contrast, the DAPT study showed an increase in
mortality by an extended course of treatment,
and the subgroup analysis by Yeh et al. (1) strongly
suggests that the excess of fatality originates from
patients presenting without myocardial infarction.
In this patient subset, prolonged DAPT duration was
associated to a 43% mortality increase. However, the
interaction testing for mortality did not reach the
formal level of signiﬁcance (Pint: 0.13). Importantly,
interaction testing is known to be underpowered, and
